tumor progression enhances the oncogenic capacity of advanced ovarian cance

Cuilan Li

David W Chan

Hextan Ys Ngan

Kwok-ming Yao

Pui Man Chiu

Vincent Ws Liu

CiteSeerX

CORRECTION Open Access
Correction: Reduced expression of AMPK-ß1 during
tumor progression enhances the oncogenic
capacity of advanced ovarian cancer
Cuilan Li
1,3, Vincent WS Liu
1, Pui Man Chiu
1, Kwok-Ming Yao
2, Hextan YS Ngan
1* and David W Chan
1*
Correction
After publication of this article [1] the authors noticed
an error in Figure 5A, B and D (Figure 1 here). In Figure
5A (Figure 1 here), the same image from AMPK-β1w a s
erroneously used for pAMPKα of A2780cp- β1 panel.
The correct image for pAMPKα is now provided. In
Figure 5B and D (Figure 1 here), the panel of OV2008-sh
β1 used two different sets of b-actin. The b-actin in Figure
5B (Figure 1 here) is now used for the whole panel of
OV2008-sh β1i nF i g u r e5 Ba n dD( F i g u r e1h e r e ) .T h e s e
errors were unintentionally made during figure prepa-
ration and do not in any way alter the results or conclu-
sions of this study. The authors apologize that these errors
were not detected earlier.
* Correspondence: hysngan@hku.hk; dwchan@hku.hk
1Department of Obstetrics & Gynecology, The University of Hong Kong, 6th
Floor, Professorial Block, Queen Mary Hospital, Pokfulam, Hong Kong, SAR,
People’s Republic of China
Full list of author information is available at the end of the article
© 2014 Li et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Li et al. Molecular Cancer 2014, 13:161
http://www.molecular-cancer.com/content/13/1/161Figure 1 AMPK-β1 positively regulates AMPK but negatively modulates AKT/mTOR, ERK and JNK activities. (A) AMPK-β1 overexpression
in A2780cp (C4, C5 and C11) and SKOV3 (C1, C2 and C3) cells activated AMPK (increased pAMPKα and pACC (left panel)) but reduced AKT (pAKT)
and mTOR (pmTOR and pP70S6K) activities (right panel). (B) Knockdown of AMPK-β1 in OV2008 (C2, C5 and C32) and OVCA433 (C1, C12 and
C23) cells by shRNA suppressed AMPK activity (decrease of pAMPKα and pACC (left panel)) but elevated AKT (pAKT) and mTOR (pmTOR and
pP70S6K) activities (right panel). (C) AMPK-β1 overexpression sensitizes ovarian cancer cells to an AMPK activator, metformin, during AMPK
activation. SKOV3 cells were treated with the AMPK activator, metformin, at 0-, 2-, and 10-mM concentrations. Stable clones overexpressing
AMPK-β1 (C1, C2, C4, and C5) were more sensitive to metformin (2 mM) in the presence of elevated pAMPKα compared with the two empty
vector controls (V2 and V3). (D) Depletion of AMPK-β1 activates the ERK and JNK pathways, and knockdown of AMPK-β1 in OV2008 (C2, C5 and
C32) and OVCA433 (C1, C12 and C23) cells led to an increase in JNK (pJNK) and ERK (pERK) signaling activities.
Li et al. Molecular Cancer 2014, 13:161 Page 2 of 3
http://www.molecular-cancer.com/content/13/1/161Author details
1Department of Obstetrics & Gynecology, The University of Hong Kong, 6th
Floor, Professorial Block, Queen Mary Hospital, Pokfulam, Hong Kong, SAR,
People’s Republic of China.
2Department of Biochemistry, LKS Faculty of
Medicine, The University of Hong Kong, Hong Kong, SAR, People’s Republic
of China.
3Department of Obstetrics & Gynecology of The Third Affiliated
Hospital of Guangzhou Medical University & Key Laboratory for Major
Obstetric Diseases of Guangdong Province, Guangzhou, People’s Republic of
China.
Received: 30 June 2014 Accepted: 30 June 2014
Published: 4 August 2014
References
1. Li C, Liu VWS, Chiu PM, Yao KM, Ngam HYS, Chan DW: Reduced expression
of AMPK-ß1 during tumor progression enhances the oncogenic capacity
of advanced ovarian cancer. Mol Cancer 2014, 13:49.
doi:10.1186/1476-4598-13-161
Cite this article as: Li et al.: Correction: Reduced expression of AMPK-ß1
during tumor progression enhances the oncogenic capacity of
advanced ovarian cancer. Molecular Cancer 2014 13:161.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Molecular Cancer 2014, 13:161 Page 3 of 3
http://www.molecular-cancer.com/content/13/1/161

CORRECTION Open Access

http://www.molecular-cancer.com/content/pdf/1476-4598-13-161.pdf

CORRECTION Open Access

Abstract

Similar works

Full text

Available Versions

CiteSeerX